NCT00963521

Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia in Complete Remission

Pilot Study of Therapeutic Vaccination by Leukemic Blasts in Vitro Differentiated Dendritic Cells From Patients With Acute Myelogenous Leukemia in Complete Remission

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Institut Paoli-Calmettes · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Vaccines made from dendritic cells may help the body build an effective immune response to kill cancer cells. PURPOSE: This phase I trial is studying the side effects of vaccine therapy and to see how well it works in treating patients with acute myeloid leukemia in complete remission.

Detailed description

OBJECTIVES: Primary * Assess the tolerability of autologous dendritic cell vaccine in patients with acute myelogenous leukemia in complete remission. Secondary * Evaluate the emergence of an immune response. * Determine the relapse rate. * Assess the occurrence of residual disease. OUTLINE: Patients receive increasing doses of blastic cells transformed in vitro by autologous dendritic cells (1/3 subcutaneously and 2/3 IV) every 3 weeks for up to 5 doses.

Conditions

• Leukemia

Interventions

Type	Name	Description
BIOLOGICAL	therapeutic autologous dendritic cells

Timeline

• Start date: 2008-06-01
• Primary completion: 2011-05-01
• First posted: 2009-08-21
• Last updated: 2011-05-13

Locations

1 site across 1 country: France